Economic evaluation of celecoxib in the treatment of arthrosis;Evaluación económica de celecoxib en el tratamiento de la artrosis

Atencion Farmaceutica

Volumn 4, Issue 2, 2002, Pages 72-82

  Vargas, E ^a   Laredo, L ^a   Soto, J ^a   Rejas, J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Arthrosis; Celecoxib; Conventional NSAI; Economic evaluation; Efficiency

Indexed keywords

ARTHROTEC; CELECOXIB; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FAMOTIDINE; IBUPROFEN; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; RANITIDINE;

ARTICLE; COST CONTROL; COST MINIMIZATION ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UTILIZATION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LABORATORY TEST; OSTEOARTHRITIS; PHARMACOECONOMICS; SENSITIVITY ANALYSIS;

EID: 0036280564     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Epidemiología de las enfermedades reumáticas en el Principado de Asturias
2. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs
3. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy
4. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
5. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo
6. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
8. Cost conscious prescribing of nonsteroidal antiinflammatory drugs for adults with arthritis: A review and suggestions
9. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users
10. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
11. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
12. Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
13. An endoscopic study of gastroduodenal lasions induced by nonsterodal anti-inflammatory drugs
14. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
15. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa
16. Antiinflamatorios no esteroides y protección gastrointestinal: ¿ Prescripción adecuada en atención primaria?
17. Estudio multicéntrico prescripción-indicación de antiácidos y antiulcerosos en atención primaria
18. Análisis de prescripción de antiulcerosos en un centro de salud rural
19. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
20. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
21. Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions
22. Estudio coste-efectividad de diferentes pautas de erradicación de Helicobacter pylori en pacientes diagnosticados de úlcera duodenal en un área de salud
23. Impacto económico de los efectos secundarios gastrointestinales asociados a antiinflamatortios no esteroides en el Servicio Nacional de Salud
24. Sensitivity analysis in health economic and pharmacoeconomic studies
25. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs
26. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal antiinflammatory drugs
27. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation, An overview of epidemiologic studies published in the 1990s
28. Factores de riesgo de la gastropatia por AINE
29. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis
30. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity
31. Celecoxib: A COX-2 inhibitor for the treatment of osteoarthritis and rheumatoid arthritis
32. Use of ACCESS model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway
33. Economic evaluation of celecoxib-A new cyclo-oxygenase 2 specific inhibitor in Switzerland
34. Cost-effectiveness analysis of NSAIDs vs COX-2 specific inhibitors and NSAIDs with co-treatments to prevent G-I toxicity in the treatment of RA
35. Cost-effectiveness of replacing diclofenac 75 mg BID by celecoxib 200 mg BID in patient with rheumatoid arthritis (RA)